Loading...
Market
Which region in the US will have the highest sales of FluMist nasal spray during the 2024-2025 flu season?
2
Resolution / Starting Odds
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
Regional sales data from AstraZeneca and market research firms
Story
FDA Approves First-of-its-Kind At-Home FluMist Nasal Spray
Sep 20, 2024, 07:52 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration or caregiver-administration. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. FluMist is licensed for individuals aged 2 to 49 and will be available through third-party pharmacies where users will complete a screening and eligibility assessment. The FDA's decision is part of a broader effort to expand consumer access to medicines and reduce healthcare costs and barriers.
View original story
Similar markets
Northeast • 25%
South • 25%
Midwest • 25%
West • 25%
California • 25%
Texas • 25%
Florida • 25%
New York • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
California • 25%
Texas • 25%
Iowa • 25%
Other • 25%
CVS • 25%
Walgreens • 25%
Rite Aid • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
West • 25%
Midwest • 25%
South • 25%
Northeast • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%